Clinical Trial Update: Dexrazoxane to Protect Against Hemorrhagic STEMI [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating dexrazoxane to protect against hemorrhagic STEMI in patients with acute myocardial infarction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction

Drugs mentioned

• DEXRAZOXANE (DEXRAZOXANE)

Snippet

Sponsor: Rohan Dharmakumar | Conditions: Acute Myocardial Infarction (AMI) | Phase 2 | Status: COMPLETED